You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

MOTRIN IB Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Motrin Ib, and when can generic versions of Motrin Ib launch?

Motrin Ib is a drug marketed by J And J Consumer Inc and is included in one NDA.

The generic ingredient in MOTRIN IB is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and forty suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Motrin Ib

A generic version of MOTRIN IB was approved as ibuprofen by STRIDES PHARMA on September 24th, 1986.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for MOTRIN IB?
  • What are the global sales for MOTRIN IB?
  • What is Average Wholesale Price for MOTRIN IB?
Summary for MOTRIN IB
US Patents:0
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 2
Raw Ingredient (Bulk) Api Vendors: 207
Clinical Trials: 73
Patent Applications: 4,394
What excipients (inactive ingredients) are in MOTRIN IB?MOTRIN IB excipients list
DailyMed Link:MOTRIN IB at DailyMed
Drug patent expirations by year for MOTRIN IB
Recent Clinical Trials for MOTRIN IB

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of MiamiPhase 2
Guangzhou Kangqi Medical Technology Co., LTDPhase 1
Weill Medical College of Cornell UniversityPhase 4

See all MOTRIN IB clinical trials

Pharmacology for MOTRIN IB

US Patents and Regulatory Information for MOTRIN IB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc MOTRIN IB ibuprofen TABLET;ORAL 019012-003 Dec 17, 1990 OTC Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for MOTRIN IB

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Recordati Rare Diseases Pedea ibuprofen EMEA/H/C/000549
Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.
Authorised no no no 2004-07-28
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

MOTRIN IB Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Motrin IB (Ibuprofen)

Introduction to Motrin IB

Motrin IB, containing the active ingredient ibuprofen, is a widely used nonsteroidal anti-inflammatory drug (NSAID) designed to relieve pain, reduce fever, and alleviate inflammation. It is available in various forms, including tablets, Liquid Gels, and other formulations[5].

Global Ibuprofen Market Overview

The global ibuprofen market, which includes Motrin IB, is projected to experience significant growth over the coming years.

  • Market Size and Growth: As of 2023, the global ibuprofen market was valued at USD 1.43 billion and is expected to reach USD 1.76 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 2.44% during the forecast period from 2024 to 2032[1].
  • Regional Dominance: The Asia Pacific region holds the largest share of the ibuprofen market, while North America is identified as the fastest-growing market[1].

Key Drivers of Market Growth

Several factors are driving the growth of the ibuprofen market, including:

  • Rising Urbanization and Public Awareness: Increasing urbanization and public awareness of chronic diseases such as rheumatoid arthritis, osteoarthritis, and cardiovascular diseases are significant drivers[1].
  • Healthcare Spending: Rising healthcare spending and growing consumer awareness about over-the-counter (OTC) medications contribute to the demand for ibuprofen[1].
  • Aging Population: The growing aging population, which is more prone to chronic pain conditions, also supports market growth[4].

Market Segmentation

The ibuprofen market is segmented based on various criteria:

  • By Type: The market is segmented into tablets, capsules, syrups, injections, and others. Tablets dominate the market with a 41.6% share in 2023 due to their ease of use[4].
  • By Application: The rheumatoid arthritis and osteoarthritis segment commands a significant share, followed by cancer-related applications and pain relief[4].

Price Trends and Cost Factors

The pricing of ibuprofen, including Motrin IB, is influenced by several factors:

  • Supply Chain Disruptions: Recent supply chain disruptions and plant shutdowns have led to an upward pricing trend, particularly in North America. Logistical challenges and higher production costs have further increased prices[3].
  • Consumer Costs: The cost for Motrin IB 200 mg oral tablets can range from $10.42 for 60 tablets to $17.20 for 500 tablets, depending on the quantity and pharmacy[2].

Competitive Landscape

The ibuprofen market faces competition from various angles:

  • Generic Competition: The availability of generic versions of ibuprofen impacts the market share of branded products like Motrin IB, leading to price wars and reduced profit margins[4].
  • Alternative Therapies: The presence of alternative pain management therapies also affects the market share of ibuprofen products[4].

Regulatory Challenges

The introduction of new ibuprofen products is subject to regulatory scrutiny and approval processes, which can pose challenges and potentially limit market growth[4].

Emerging Markets and Trends

  • Emerging Markets: Significant growth opportunities exist in emerging markets, particularly in regions with expanding healthcare infrastructures[4].
  • Innovations in Drug Delivery: Innovations in drug delivery systems and the expansion of the OTC market are current trends shaping the ibuprofen market[4].
  • Sustainable Packaging and Digital Marketing: There is a shift towards sustainable packaging, digital marketing, and personalized medicine approaches, which are influencing market dynamics[4].

Regional Analysis

  • North America: This region leads the market with over 41.6% share in 2023, driven by a robust healthcare infrastructure and a well-established pharmaceutical industry[4].
  • Asia Pacific: The Asia Pacific region, while being the largest market, also presents significant growth opportunities due to its large population and increasing healthcare needs[1].

Financial Projections

  • Market Size Projections: One report estimates the ibuprofen market to reach approximately USD 205.6 million by 2033, growing at a CAGR of 7.8% from 2024 to 2033[4].
  • Revenue Growth: The revenue growth is driven by increasing demand for pain management solutions and the efficacy of ibuprofen in treating various conditions[4].

Consumer and Patient Assistance Programs

  • Pricing and Discounts: Consumers can benefit from various pricing options, coupons, copay cards, and patient assistance programs, although specific programs for Motrin IB may be limited[2].
  • Healthcare Provider Guidance: Healthcare providers often have more information on available programs and can guide patients on cost-effective options[2].

Key Takeaways

  • The global ibuprofen market, including Motrin IB, is expected to grow significantly due to rising urbanization, public awareness of chronic diseases, and increasing healthcare spending.
  • The market is segmented by type and application, with tablets being the dominant form.
  • Price trends are influenced by supply chain disruptions, production costs, and regulatory factors.
  • Emerging markets and innovations in drug delivery systems present significant growth opportunities.
  • Regulatory challenges and generic competition impact market dynamics.

Frequently Asked Questions (FAQs)

Q: What is the current market size of the global ibuprofen market? A: As of 2023, the global ibuprofen market was valued at USD 1.43 billion[1].

Q: What is the projected growth rate of the ibuprofen market? A: The market is expected to grow at a CAGR of 2.44% from 2024 to 2032[1].

Q: Which region has the largest share of the ibuprofen market? A: The Asia Pacific region holds the largest share of the ibuprofen market[1].

Q: What are the main drivers of the ibuprofen market growth? A: Key drivers include rising urbanization, public awareness of chronic diseases, and increasing healthcare spending[1].

Q: Are there any patient assistance programs available for Motrin IB? A: While specific patient assistance programs for Motrin IB may be limited, consumers can benefit from various pricing options, coupons, and copay cards[2].

Cited Sources

  1. Straits Research: Global Ibuprofen Market Size, Top Share, CAGR of 2.44%, Report ...
  2. Drugs.com: Motrin IB Prices, Coupons, Copay Cards & Patient Assistance
  3. Procurement Resource: Ibuprofen Price Trend, Index, News, Chart, Database
  4. Market.us: Ibuprofen Market Size, Share, Growth | CAGR Of 7.8%
  5. Motrin.com: What Is Motrin (Ibuprofen)?

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.